Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17428
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMacdonell, Richard A L-
dc.contributor.authorNagels, Guy-
dc.contributor.authorLaplaud, David-Axel-
dc.contributor.authorPozzilli, Carlo-
dc.contributor.authorde Jong, Brigit-
dc.contributor.authorMartins da Silva, Ana-
dc.contributor.authorNicholas, Richard-
dc.contributor.authorLechner-Scott, Jeannette-
dc.contributor.authorGaebler, Julia A-
dc.contributor.authorAgarwal, Sonalee-
dc.contributor.authorWang, Ping-
dc.contributor.authorYeh, Michael-
dc.contributor.authorHovenden, Maria-
dc.contributor.authorSoelberg Sørensen, Per-
dc.date2015-10-07-
dc.date.accessioned2018-04-12T01:50:39Z-
dc.date.available2018-04-12T01:50:39Z-
dc.date.issued2016-06-
dc.identifier.citationMultiple sclerosis (Houndmills, Basingstoke, England) 2016; 22(7): 944-954-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/17428-
dc.description.abstractMultiple sclerosis (MS) is a debilitating disease that negatively impacts patients' lives. ENABLE assessed the effect of long-term prolonged-release (PR) fampridine (dalfampridine extended release in the United States) treatment on patient-perceived health impact in patients with MS with walking impairment. ENABLE was a 48-week, open-label, Phase 4 study of PR-fampridine 10 mg twice daily. Patients who showed any improvement in Timed 25-Foot Walk walking speed at weeks 2 and 4 and any improvement in 12-item MS Walking Scale score at week 4 remained on treatment. The primary endpoint was change from baseline in 36-Item Short-Form Health Survey (SF-36) physical component summary (PCS) score. At week 4, 707/901 (78.5%) patients met the criteria to remain on treatment. Patients on treatment demonstrated significant and clinically meaningful improvements in SF-36 PCS scores from baseline (mean change (95% confidence interval)) to week 12 (4.30 (3.83, 4.78); p < 0.0001), week 24 (3.75 (3.23, 4.27); p < 0.0001), week 36 (3.46 (2.95, 3.97); p < 0.0001), and week 48 (3.24 (2.72, 3.77); p < 0.0001). Significant improvements from baseline were also demonstrated in secondary health measures in patients on treatment. PR-fampridine improved patient-perceived physical and psychological health impact of MS measured in a real-life setting.-
dc.language.isoeng-
dc.subjectFampridine-
dc.subjectmultiple sclerosis-
dc.subjectpatient-reported outcome-
dc.subjectquality of life-
dc.titleImproved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.-
dc.typeJournal Article-
dc.identifier.journaltitleMultiple sclerosis (Houndmills, Basingstoke, England)-
dc.identifier.affiliationDepartment of Neurology, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia-
dc.identifier.affiliationNational Multiple Sclerosis Center Melsbroek and Center for Neurosciences, Vrije Universiteit Brussel, Belgium-
dc.identifier.affiliationCentre Hospitalier Universitaire de Nantes, Hôpital G. et R. Laennec, France-
dc.identifier.affiliationThe Department of Neurology and Psychiatry, Sapienza University, Italy-
dc.identifier.affiliationRadboud University Medical Center, Nijmegen and the Neurology Department of Jeroen Bosch Hospital, The Netherlands-
dc.identifier.affiliationNeurosciences Department, Hospital Santo António-Centro Hospitalar do Porto, Portugal-
dc.identifier.affiliationImperial College, UK-
dc.identifier.affiliationHunter Medical Research Institute, The University of Newcastle, Australia-
dc.identifier.affiliationBiogen, Cambridge, MA, USA-
dc.identifier.affiliationExcel Scientific Solutions, Southport, CT, USA-
dc.identifier.affiliationDanish Multiple Sclerosis Center, Copenhagen University Hospital Rigshospitalet, Denmark-
dc.identifier.doi10.1177/1352458515606809-
dc.identifier.pubmedid26447066-
dc.type.austinClinical Trial, Phase IV-
dc.type.austinJournal Article-
dc.type.austinMulticenter Study-
dc.type.austinObservational Study-
dc.type.austinResearch Support, Non-U.S. Gov't-
local.name.researcherMacdonell, Richard A L
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptNeurology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

20
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.